Related references
Note: Only part of the references are listed.Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis
Wenju Chang et al.
CELL STEM CELL (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
Lola Fashoyin-Aje et al.
ONCOLOGIST (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Prognostic value of PD-L1 expression in patients with primary solid tumors
Xiao Xiang et al.
ONCOTARGET (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
Peixin Dong et al.
FRONTIERS IN ONCOLOGY (2018)
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Geoffrey J. Markowitz et al.
JCI INSIGHT (2018)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau et al.
NATURE COMMUNICATIONS (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Human Tumor-infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Louise A. Elliott et al.
FRONTIERS IN IMMUNOLOGY (2017)
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Jan Willem Kleinovink et al.
ONCOIMMUNOLOGY (2017)
Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer
Xiaowei Chen et al.
ONCOIMMUNOLOGY (2017)
Cisplatin/5-FU (CF) +/ panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD /BDGO/EORTC phase III trial (POWER).
Markus H. Moehler et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer
Dingzhi Wang et al.
CANCER RESEARCH (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer
Zina Dubeykovskaya et al.
NATURE COMMUNICATIONS (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins
Linda Wang et al.
JOURNAL OF IMMUNOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inhibition of Gastric Carcinogenesis by the Hormone Gastrin Is Mediated by Suppression of TFF1 Epigenetic Silencing
Hiroyuki Tomita et al.
GASTROENTEROLOGY (2011)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice
Shuiping Tu et al.
CANCER CELL (2008)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
Je-In Youn et al.
JOURNAL OF IMMUNOLOGY (2008)
Inflammation, atrophy, and gastric cancer
James G. Fox et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
